Quinoline-based promising anticancer and antibacterial agents, and some metabolic enzyme inhibitors

dc.contributor.authorOkten, Salih
dc.contributor.authorAydın, Ali
dc.contributor.authorKoçyiğit, Ümit M.
dc.contributor.authorCakmak, Osman
dc.contributor.authorErkan, Sultan
dc.contributor.authorAndac, Cenk A.
dc.contributor.authorTaslimi, Parham
dc.contributor.authorTaslimi, Parham
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T13:23:11Z
dc.date.created2020
dc.date.issued2020
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.description.abstractA series of substituted quinolines was screened for their antiproliferative, cytotoxic, antibacterial activities, DNA/protein binding affinity, and anticholinergic properties by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation, lactate dehydrogenase cytotoxicity, and microdilution assays, the Wolfe-Shimmer equality method, the Ellman method, and the esterase assay, respectively. The results of the cytotoxic and anticancer activities of the compounds displayed that 6-bromotetrahydroquinoline (2), 6,8-dibromotetrahydroquinoline (3), 8-bromo-6-cyanoquinoline (10), 5-bromo-6,8-dimethoxyquinoline (12), the novelN-nitrated 6,8-dimethoxyquinoline (13), and 5,7-dibromo-8-hydroxyquinoline (17) showed a significant antiproliferative potency against the A549, HeLa, HT29, Hep3B, and MCF7 cancer cell lines (IC50 = 2-50 mu g/ml) and low cytotoxicity (similar to 7-35%) as the controls, 5-fluorouracil and cisplatin. The compound-DNA linkages are hyperchromic or hypochromic, causing variations in their spectra. This situation shows that they can be bound to DNA with the groove-binding mode, withK(b)value in the range of 2.0 x 10(3)-2.2 x 10(5) M-1. Studies on human Gram(+) and Gram(-) pathogenic bacteria showed that the substituted quinolines exhibited selective antimicrobial activities with MIC values of 62.50-250 mu g/ml. All tested quinoline derivatives were found to be effective inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase I and II isoforms (hCA I and II), withK(i)values of 46.04-956.82 nM for hCA I, 54.95-976.93 nM for hCA II, and 5.51-155.22 nM for AChE. As a result, the preliminary data showed that substituted quinolines displayed effective pharmacological features. Molecular docking studies were performed to investigate the binding modes and interaction energies for compounds2-17with AChE (PDB ID: 4EY6), hCA I (PDB ID: 1BMZ), and hCA II (PDB ID: 2ABE).
dc.identifier.doi10.1002/ardp.202000086
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue9
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidaydin, ali/0000-0002-9550-9111
dc.identifier.orcidKocyigit, Umit Muhammet/0000-0001-8710-2912
dc.identifier.orcidAndac, Cenk A./0000-0002-4545-3500
dc.identifier.orcidOkten, Salih/0000-0001-9656-1803;
dc.identifier.pmid32537757
dc.identifier.scopus2-s2.0-85090079624
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ardp.202000086
dc.identifier.urihttps://hdl.handle.net/11772/22730
dc.identifier.volume353
dc.identifier.wosWOS:000567558100004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectAcetylcholinesterase Enzyme Inhibition
dc.subjectAntibacterial
dc.subjectAnticancer Activity
dc.subjectCarbonic Anhydrase Enzyme Inhibition
dc.subjectDna Binding
dc.subjectMolecular Docking
dc.subjectQuinolone
dc.titleQuinoline-based promising anticancer and antibacterial agents, and some metabolic enzyme inhibitors
dc.typeArticle
dc.wosindexScience Citation Index Expanded (SCI-EXPANDED)
dc.wosindexIndex Chemicus (IC)
dspace.entity.typePublication
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscoverydadfa319-65b8-4543-92b4-bea49e0139e9

Dosyalar